|
|
|
|
| LEADER |
02736nam a2200481 4500 |
| 001 |
978-3-319-33673-2 |
| 003 |
DE-He213 |
| 005 |
20200229233518.0 |
| 007 |
cr nn 008mamaa |
| 008 |
190930s2019 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319336732
|9 978-3-319-33673-2
|
| 024 |
7 |
|
|a 10.1007/978-3-319-33673-2
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL
|2 thema
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Tumor Angiogenesis
|h [electronic resource] :
|b A Key Target for Cancer Therapy /
|c edited by Dieter Marmé.
|
| 250 |
|
|
|a 1st ed. 2019.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2019.
|
| 300 |
|
|
|a 63 illus., 58 illus. in color. eReference.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 520 |
|
|
|a This exhaustive work shows that new therapies using anti-angiogenic drugs are of particular importance because they can be used against many different types of cancer, as tumor angiogenesis seems to be involved in most if not all solid metastasizing malignancies. The first part of this book summarizes the knowledge acquired on the molecular entities that play a role in tumor angiogenesis and their mechanisms of action. Furthermore, the identification of molecular markers and their validation as predictive and/or prognostic tools is reviewed. In the second and most important part, the clinical applications of anti-angiogenic treatments are documented for a wide variety of tumors. In particular, the modes of combination with other targeted and/or cytotoxic cancer therapies are presented.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Oncology .
|
| 650 |
|
0 |
|a Molecular biology.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
1 |
4 |
|a Cancer Research.
|0 http://scigraph.springernature.com/things/product-market-codes/B11001
|
| 650 |
2 |
4 |
|a Oncology.
|0 http://scigraph.springernature.com/things/product-market-codes/H33160
|
| 650 |
2 |
4 |
|a Molecular Medicine.
|0 http://scigraph.springernature.com/things/product-market-codes/B1700X
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|0 http://scigraph.springernature.com/things/product-market-codes/B21007
|
| 700 |
1 |
|
|a Marmé, Dieter.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer Nature eReference
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319336725
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319336718
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-33673-2
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
